919284-64-3 Usage
Uses
Used in Pharmaceutical Industry:
TERT-BUTYL 4-(BENZYLOXYMETHYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is used as a building block in organic synthesis for the production of various drugs. It serves as a key intermediate in the development of molecules with potential therapeutic properties, contributing to the advancement of new pharmaceutical agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, TERT-BUTYL 4-(BENZYLOXYMETHYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is employed as a valuable component in the synthesis of bioactive compounds. Its structural features allow for the creation of diverse chemical entities that can be further optimized for improved pharmacological activity and selectivity.
Used in Drug Discovery and Development:
TERT-BUTYL 4-(BENZYLOXYMETHYL)-4-CYANOPIPERIDINE-1-CARBOXYLATE is utilized in drug discovery and development processes to create novel chemical entities with potential therapeutic applications. Its unique structural elements can be leveraged to design and synthesize new drug candidates that address unmet medical needs.
Check Digit Verification of cas no
The CAS Registry Mumber 919284-64-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,9,2,8 and 4 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 919284-64:
(8*9)+(7*1)+(6*9)+(5*2)+(4*8)+(3*4)+(2*6)+(1*4)=203
203 % 10 = 3
So 919284-64-3 is a valid CAS Registry Number.
919284-64-3Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS CONTAINING AN INDOLE CORE
-
Page/Page column 86, (2011/06/26)
Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides
Zhao, Zhijian,O'Brien, Julie A.,Lemaire, Wei,Williams Jr., David L.,Jacobson, Marlene A.,Sur, Cyrille,Pettibone, Doug J.,Tiller, Philip R.,Smith, Sheri,Hartman, George D.,Wolkenberg, Scott E.,Lindsley, Craig W.
, p. 5968 - 5972 (2007/10/03)
This Letter describes the synthesis and SAR, developed through an iterative analog library approach, of potent and selective non-sarcosine-derived GlyT1 inhibitors.
